T-lineage blast crisis of chronic myelogenous leukemia: simple record of 4 cases

Kartika W. Taroeo-Hariadi, Eiji Tatsumi, Mardiah S. Hardianti, Kaho Furuta, Meilani Syamprawati, Bambang Karsono, Takayuki Ishikawa, Hiroki Yabe, Ken-Ichi Nagai, Takayuki Takahashi, Yuji Kishimoto

Abstrak


Keywords: Chronic Myelogenous Leukemia (CML), Blastic Crisis (BC), T-lineage, bcr-abl fusion gene, CD3ε, TdT

Chronic Granulocytic Leukemia (CGL) is a well-defined myeloproliferative disorder associated in more than 90% of cases with the Philadelphia chromosome (Ph). CGL originates from multipotent hematopoietic stem cell. Progeny of this transformed cell include granulocytic, erythroid, megakaryocytic, monocytic cells, eosinophils, and lymphocytes. CGL initially present with indolent or chronic phase course, easily controlled with therapy. After a variable period of time, usually 2-4 years, patients will enter into an...
accelerated phase and result in a terminal phase, referred to as blast crisis (blast transformation, BC).\(^3\) Blast crisis is characterized by the appearance of at least 20% blast cells in the peripheral blood and bone marrow nucleated cells, and extra medullary blast proliferation, or aggregation of blast in bone marrow biopsy specimen with localized immature blast and refractor splenomegaly.\(^4,5\) The blast crisis cells from majority of patients are thought to resemble acute myeloblastic leukemia, and one-third of patients’ blasts morphologically resemble the blasts of acute lymphoblastic leukemia (ALL).\(^1,6\) The blast in this lymphoid BC commonly show L1 or L2 (FAB morphology), have positive terminal deoxynucleotidyl transferase (TdT) results, and pre-B cell immunophenotypic profile (CD19+, CD20- or low +, CD10+, cytoplasmic Ig ±, surface Ig -).\(^7\) In contrast, CML-BC of T-lineage has been only very rarely reported. CML-BC of erythroid or megakaryocyte lineage or CML-BC with very undifferentiated feature showing no lineage marker, has also been reported only very rarely.\(^8\) Here, we showed a simple summary of 4 cases of T-lineage CML-BC.

**METHODS**

Four samples from T-lineage CML-BC CGL had been collected from 1987 to 2004. Diagnoses of blast crisis was determined according to WHO criteria, morphological features, cytochemistry, and cell–surface antigen analysis. In all cases, the chromosomal analysis revealed the presence of t(9;22)(q34;q11) at presentation.

Bone marrow or peripheral bloods were collected into preservative-free heparin, and erythrocytes are removed by density gradient sedimentation in Ficoll-Hypaque. Interface cells were washed twice in PBS and added with RPMI 1640 containing 10% FCS.\(^8\)

**Cell surface antigen analysis**

Cell-surface antigen analysis were detected at presentation by direct and indirect cell-surface immunofluorescence with a total of 20 monoclonal antibodies to identify antigen of T-cell, B-cell, myeloid cell, precursor cells, monocyte, and megakaryoblastic cell: NUIa (HLA-DR), NUTer (CD2), NUTpan (CD5), Leu4 (CD3), NUTH1 (CD4), NUT-S/C (CD8), NU-B2 (CD20), NUN1 (CD10), MCS2 (CD13), were purchased from Nichirei Tokyo, Japan), BA-1 (CD24) was from Boehringer Manheim (Manheim, Germany); Leu9 (CD7), Leu12 (CD19), Leu-M1(CD15), were from Becton-Dickinson (Mountain View, CA); Mo1(CD11b), My4 (CD14), My9 (CD33), were from Coulter (Hialeah, FL). OKT10 (CD38) was from Fujisawa, OKM5 (CD36) was from Ortho-mune, HIP 8 (CD 41a), HIP1 (CD42), were from Becton Dickinson.

One hundred micro liter of RPMI 1640 (Nissui, Tokyo, Japan) containing 4x10\(^7\) cells was incubated with appropriately diluted conjugated or unconjugated monoclonal antibodies. Fluorescence isothiocyanate (FITC)-conjugated F(ab’\(^2\)) antiratouse IgG was used for indirect immunofluorescence. Heat aggregated human IgG (50 mg/ml)(Venilon; Fujisawa, Osaka, Japan) was added ten minutes before each incubation to block Fc receptor. Incubation was performed for 30 minutes at 4°C. The stained cells were assayed with an EPICS-C flowcytometer (Couler).\(^8\)

**Terminal Deoxynucleotidyl Transferase Reverse Transcription Polymerase Chain Reaction assay (TdT RT-PCR)**

Complimentary DNA (cDNA) was synthesized using random primer (TaKara kypp, Japan) and M-MLV reverse transcriptase (GibcoBRL, NY,USA) from 2μg of sample derived RNA extracted by Trizol (Invitrogen, Carsbald, CA, USA) as previously prepared.\(^9\) Terminal Deoxynucleotidyl Transferase (TdT) was determined by Reverse Transcription-Polymerase Chain Reaction(RT-PCR) assay using primer TdT1 5’ATG ATA CCC TTC ACC TCG GAC 3’ (bp211-221) and TdT 2 5’GTC ACC CAC ATT GTA GCA GAG3’ (bp 623-625). PCR was carried out by using Gene Amp\(^\text{TM}\) DNA amplification Reagent Kit with Ampli Taq\(^\text{TM}\) (Takara Shuzo, Kyoto, Japan). TdT RT-PCR was performed with a DNA thermal cycler (Takara Shuzo). After 5 min at 95°C, a 30 cycles PCR was performed under the following conditions: a denaturation step at 95°C for 60s, an annealing step at 65°C for 60s, and extension steps at 72°C for 2 min (10 min in the last cycle).

**CD3ε RT-PCR assay**

CD3 was identified with monoclonal antibody by flowcytometry or by RT PCR CD3ε. RT-PCR CD3 were performed using primer 5’GTG ACC ACA G3’ (bp 166-187) and 5’GGC CTT TCT ATT CTT GCT CCA C 3’ (bp 504-525) under the following condition: after 5 min at 94°C, a 30 cycles of PCR was performed under the following
conditions; a denaturation step at 94°C for 60s, an annealing steps at 63°C for 60s, and an extension step at 72°C for 1 min (8 min in the last cycle).\textsuperscript{10}

**BCR-ABL multiplex PCR**

BCR-ABL fusion gene were determined with BCR-ABL multiplex PCR, using 4 primer BCR-C 5’ ACC GCA TGT TCC GGG ACA AAA G3’, B2B 5’ ACA GAA TTC GCT GAC CAT CAA TAA G3’, C5e-5’ATA GGA TCC TTT GCA ACC GGG TCT GAA3’, CA3- 5’TGT TGA CTG GCG TGA TGT AGT TGC TTG G3’ as previously described.\textsuperscript{11}

All the amplified PCR product (5 µl) were electrophoresed in 2% agarose gel stained with ethidium bromide and observed under the UV light transiluminator.

**RESULT**

There were 4 patients of T-lineage CML-BC (Table 1). All of them were negative for CD4, CD8, CD3, CD10, CD19, CD20, CD14, and CD15. The results of cell surface antigen (CSA) at presentation showed that 1 case was CD7+, CD5-, and CD2-; 1 case CD7+, CD5+, and CD2-; and 2 cases CD7+, CD5+ and CD2+ indicating the phenotype of pre-(pro-) thymic stage phenotype.

Expression of CD38 in T-lineage blast crisis were seen in all tested patient. CD13 expression were positive in all CD7+ CD5+ CD2- /CD7+CD5-CD2- and in 50% of CD7+ CD5+ CD2+. CD 33 were expressed in 2 patients; one with CD7+CD5-CD2-, one with CD7+CD5+CD2+. HLA-DR was positive in 3 patients, and CD11b were positives in all patients.

**Table 1.** Sample characteristics and immunophenotyping results of Blast Crisis Chronic Granulocytic Leukemia Patients

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Pt 1</th>
<th>Pt 2</th>
<th>Pt 3</th>
<th>Pt 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>65</td>
<td>20</td>
<td>65</td>
<td>72</td>
</tr>
<tr>
<td>Sex</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>Date of sample exm</td>
<td>16-4-1990</td>
<td>13-11-1987</td>
<td>2-10-1987</td>
<td>26-7-1995</td>
</tr>
<tr>
<td>Sample source</td>
<td>PB</td>
<td>PB</td>
<td>PB</td>
<td>PB</td>
</tr>
<tr>
<td>HLA-DR†</td>
<td>+</td>
<td>-</td>
<td>±</td>
<td>-</td>
</tr>
<tr>
<td>TdT*</td>
<td>-</td>
<td>_</td>
<td>+</td>
<td>- NT</td>
</tr>
<tr>
<td>CD38†</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>NT</td>
</tr>
<tr>
<td>CD7†</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>-</td>
</tr>
<tr>
<td>CD5†</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>-</td>
</tr>
<tr>
<td>CD2†</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>NT</td>
</tr>
<tr>
<td>CD3†</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CD3ε RT PCR*</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>NT</td>
</tr>
<tr>
<td>CD13†</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>++</td>
</tr>
<tr>
<td>CD33†</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>±</td>
</tr>
<tr>
<td>CD11b</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>NT</td>
</tr>
<tr>
<td>CD36†</td>
<td>±</td>
<td>±</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>CD41†</td>
<td>-</td>
<td>±</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>CD42†</td>
<td>-</td>
<td>-</td>
<td>NT</td>
<td>NT</td>
</tr>
</tbody>
</table>

†Antigen expression determined in an indirect immunofluoresence assay ( - ) 0-15% fluorescent cells (±) 16-25% (+) 26-40% (++) 41-100%
NT: not tested

*Antigen expression determined by RT-PCR  in 2004

CD4,CD8, CD19, CD20, CD10, CD14,CD15 were always negative
Surface marker CD3 were always negatives in all tested patients, but CD3ε RT PCR revealed a positive expression in all tested patients.

TdT was positive in only one patient. TdT RT-PCR result were shown in Figure 2.

Table 2. BCR-abl Multiplex RT-PCR result

<table>
<thead>
<tr>
<th></th>
<th>Pt 1</th>
<th>Pt 2</th>
<th>Pt 3</th>
<th>Pt 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>e1a2 (481bp)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>b3a2 (385bp)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>b2a2 (310bp)</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>BCR (808 bp)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Two patients were positive for BCR-ABL fusion gene b2a2 transcripts, one patient was positive for e1a2 transcript, and one was negative for BCR-ABL fusion gene (Table 2). Gel electrophoresis for RT-PCR BCR-ABL result is presented in Figure 3.

DISCUSSION

Blast transformation eventually develop in both Ph positive or negative CGL patients. 

Blast transformation in CGL is characterized by cell line heterogeneity so that it can be myeloid, lymphoid, megakaryocyte, or erythroid crisis. It reveals that transformation derived from pluripotential haematopoetic stem cell and also that the blast cell population has capacity to differentiate along several pathway.

The phenotypic feature of CML usually positive for mature myeloid marker, and the phenotype will change according to the cell line transformation.

The incidence of T-lineage blast crisis is low. There were few cases found and but none of T-cell phenotype had been interpreted, although T cell antigen were present 5-30% of all cases of blast crisis. T cell-lineage blast crisis usually expresses surface marker resembles to T-ALL which is TdT+, CD10-, HLA DR-, CD7+ (all T cell marker positive can be present), and positive TCR gene arrangement.

Rodriguez-Pinilla et al previously reported a chronic myelogenous leukemia with early progression to extramedullary T-lymphoblastic crisis (TdT+ CD3+ CD34+ CD43+, PCR p210 for BCR ABL+, and clonal rearrangement of TCRγ.

In our cases, all B-cell phenotype marker was negative, and T-cell phenotype showed pre-thymic stage. CD13 positiveness in our cases related to the immaturity of T-cell. CD 33 was positive in 2 cases. CD11b was positive in all patients. Previous study reported that CD11b was not expressed in CD7+CD5-CD2-, but expressed in all CD7+CD5+CD2- T-ALL/LBL.

Usually TdT is dominantly expressed in most immature hematopoetic cell stage, eg in pro T-cell / pro B-cell stage of maturation, but some previous studies reported that in thymic stage (CD3-CD4-CD8, CD3-CD4+CD8+, CD3+CD4±CD8± lymphoblast) TdT was still almost always expressed. Negative TdT are more easily found in CD7+CD5-CD2-lymphoblast. Our negative TdT cases might be from positive myeloid marker expressing-blasts and the only one positive TdT case was negative myeloid marker expressing-blast. More samples are needed to get the similar conclusion as previously reported that TdT transcripts in myeloid marker + ALL is reduced than in myeloid marker – ALL.

PCR CD3ε is done to detect the expression of cytoplasmic CD3 transcript. CD3ε transcript was positive, while CD3 was still negative means that the CD3ε molecule has been detected in cytoplasm but the CD3 molecule has not been synthesized and expressed in surface membrane.

The Ph negative blast crisis, like our case, is also unclear in incidence. Previously reported Ph negative blast crisis showed more mature/thymic stage, HLA- DR negative, and TdT negative. It is thought that Ph- negative CGL clone evolved to T cell malignancy, therefore it occurs in a pluripotent stem cell, similar to the situation observed with Ph-positive CGL. The stem cell then differentiates towards the T-lineage and transform there.
**Figure 1.** PCR $\beta$-actin 500 bp on 4 patients T-lineage BC CML.

**Figure 2.** Expression of TdT and CD3ε. Bay91 was used as positive control, and U266 as negative control for TdT. HPB ALL was used for positive control and Bay91 as negative control for CD3ε. The marker was 100 bp ladder, the brightest one was 500 bp.
T-lineage blast crisis of CML

Figure 3. Expression of BCR ABL transcripts. Raji was used as negative control. All BCR band were positive indicated that cDNA quality is good enough. Pt 4 showed negative result for BCR-ABL transcripts.

REFERENCES
